THE GLOBAL MARKET FOR FIXED-DOSE COMBINATION DRUGS FOR LEADING DISEASES

Table of Contents

• INTRODUCTION
  • OBJECTIVES AND GOALS OF STUDY
  • CONTRIBUTION OF THE STUDY AND FOR WHOM
  • STUDY SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • OTHER MARKET RESEARCH REPORTS RECENTLY PUBLISHED BY THE AUTHOR
• EXECUTIVE SUMMARY
• OVERVIEW
  • DEFINITION OF A COMBINATION DRUG
  • ADVANTAGES OF FIXED-DOSE COMBINATION DRUGS
  • POTENTIATION AND CANCELLATION
  • DECREASED DOSING MEANS BETTER COMPLIANCE AND LOWER ADMINISTRATIVE COSTS
  • COMBINATION DRUGS TARGETING INFECTIOUS AGENTS RATHER THAN BODY TISSUES
  • THE DISADVANTAGES OF FIXED-DOSE COMBINATION DRUGS
  • REGULATIONS RELATING TO FIXED-DOSE COMBINATION DRUGS
  • INCENTIVES AND BARRIERS TO THE DEVELOPMENT OF FIXED-DOSE COMBINATION DRUGS
  • MARKET-RELATED ADVANTAGES OF FIXED-DOSE COMBINATION DRUGS
  • THE CHALLENGES OF MANUFACTURING FIXED-DOSE COMBINATION DRUGS
  • LEGAL/INTELLECTUAL PROPERTY ISSUES RELATING TO FIXED-DOSE COMBINATION PRODUCTS
• PRODUCTS AND APPLICATIONS
  • CARDIOVASCULAR DISEASES
  • INFECTIOUS DISEASES
  • PSYCHIATRIC DISEASES
  • CARDIOVASCULAR DISEASES
    • HYPERTENSION
      • Prevalence of Hypertension Worldwide
      • Improved Control of Hypertension Needed
      • The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
      • The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
      • Leading Single-Compound Antihypertensive Agents
      • Fixed-Dose Combination Antihypertensive Drugs
      • Drug Categories Commonly Used in Fixed-Dose Combination Antihypertensive Drugs
        • Angiotensin-Converting Enzyme Inhibitors
        • Angiotensin II Receptor Blockers
        • Beta Blockers
        • Calcium Channel Blockers
        • Diuretics
      • The Market for Fixed-Dose Combination Antihypertensive Products
      • Fixed-Dose Combination Drug Products in Phase II or Later Development for the Treatment of Hypertension
        • Daiichi Sankyo Files NDA with FDA for New Fixed-Dose Combination Antihypertensive Drug
        • Toprol-XL/HCTZ
    • HYPERCHOLESTEROLEMIA
      • Relationship of Cholesterol to Cardiovascular Disease
      • Fixed-Dose Combination Lipid-Lowering Drugs
      • Marketed Statin Drugs
      • The First Fixed-Dose Combination Product to Treat Hypercholesterolemia Introduced
      • The Market for Fixed-Dose Combination Drugs to Treat Hypercholesterolemia
      • A Potential Blockbuster Fails Late-Stage Trials
      • Another Statin Fixed-Dose Combination Product Hits a Snag
      • Products in Development
        • Combination of Crestor and TriCor for the Treatment of Hypercholesterolemia
        • Simcor
        • Three-Drug "Polypill" in Development
  • DIABETES
    • FIXED-DOSE COMBINATION DRUGS FOR DIABETES INTRODUCED
      • Avandamet
      • Glucovance
      • Metaglip
    • THREE NEW FIXED-DOSE COMBINATION PRODUCTS INTRODUCED IN 2005 AND 2006
    • THE MARKET FOR FIXED-DOSE COMBINATION DRUGS TO TREAT DIABETES
    • FIXED-DOSE COMBINATION DRUGS IN DEVELOPMENT
  • INFECTIOUS DISEASES
    • LEADING FIXED-DOSE COMBINATION ANTIBIOTIC DRUGS
      • Augmentin
      • Bactrim
      • Primaxin
      • Synercid
      • Zosyn
    • THE MARKET FOR FIXED-DOSE COMBINATION DRUGS TO TREAT BACTERIAL INFECTIONS
    • HELICOBACTER PYLORI INFECTION
      • Fixed-Dose Combination Therapy for the Treatment of Helicobacter Pylori Infections/Duodenal Ulcers
        • OD-PEP
        • Pylera
      • The Market for Fixed-Dose Combination Drugs to Treat H. Pylori Infections
    • HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)
      • HIV and AIDS Statistics
      • HIV Infection and AIDS Cases in the U.S.
      • Treatments for HIV Infection/AIDS
      • Categories of Drugs Used in Fixed-Dose Combination Products for the Treatment of HIV/AIDS
        • Transcriptase Inhibitors
          • Nonnucleoside Reverse Transcriptase Inhibitors
          • Nucleoside Reverse Transcriptase Inhibitors
          • Nucleotide Reverse Transcriptase Inhibitors
          • Protease Inhibitors
      • Side Effects of Marketed HIV Drugs
      • HIV/AIDS Drugs Introduced to the U.S. Market from 2003 through 2006
      • Leading Marketers of HIV/AIDS Drugs
        • Leaders in the Nucleoside Reverse Transcriptase Inhibitor Class
      • Dosing and Compliance Challenges
      • The Ideal Dosing Regimen and the Role of Fixed-Dose Combination Products
      • The Number of Salvage Patients Continues to Increase
      • Fixed-Dose Combination Drugs to Treat HIV/AIDS
        • Combination Products Emerge as Preferred Treatment
        • Atripla
        • Combivir
        • Epzicom
        • Kaletra
        • Trizivir
        • Truvada
        • FDA Approves Aurobindo Three-in-One Fixed-Dose Combination Drug for AIDS Relief Program
      • The Market for Fixed-Dose Combination Drugs for the Treatment of HIV Infection/AIDS
      • Fixed-Dose Combination Drugs in Phase II Development for the Treatment and/or Prevention of HIV Infection/AIDS
    • TUBERCULOSIS
      • Fixed-Dose Combination Drugs Used to Treat Tuberculosis
  • PSYCHIATRIC DISORDERS
    • DEPRESSION
      • Recently Introduced Fixed-Dose Combination Products for the Treatment of Depression
    • THE MARKET FOR FIXED-DOSE COMBINATION PRODUCTS TO TREAT PSYCHIATRIC DISORDERS
    • FIXED-DOSE COMBINATION PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
      • 372475
      • 773812
      • Contrave
      • Excalia
      • Symbyax
    • FIXED-DOSE COMBINATION PRODUCTS FOR THE TREATMENT OF ALZHEIMER' S DISEASE
  • RESPIRATORY DISEASES
    • ASTHMA
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    • CURRENTLY MARKETED PRODUCTS FOR THE TREATMENT OF ASTHMA
      • Anti-Inflammatory Drugs Used to Treat Asthma
        • Corticosteroids
        • Leukotriene Modifiers
        • IgE Inhibitors
        • Phosphodiesterase Inhibitors
        • Mast-Cell Inhibitors
      • Efficacy of Available Drugs
      • Fixed-Dose Combination Asthma Treatments
        • Advair/Seretide
        • Foster
        • Symbicort
    • THE MARKET FOR DRUGS TO TREAT ASTHMA AND COPD
      • The Market for Drugs to Treat Asthma
      • The Market Drugs to Treat COPD
      • The Market For Fixed-Dose Combination Drugs To Treat Asthma/COPD
    • FIXED-DOSE COMBINATION PRODUCTS IN PHASE II OR LATER DEVELOPMENT TO TREAT ASTHMA AND COPD
      • Alvesco Combo
      • Flutiform
      • Mometasone/Formoterol
      • Super Advair
      • VR315
  • INDUSTRY
    • THE NUMBER OF BLOCKBUSTER DRUGS ON THE WORLDWIDE PHARMACEUTICAL MARKET APPROACHES 100
    • U.S. PHARMACEUTICAL INDUSTRY GROWTH EXPECTED TO INCREASE SLIGHTLY
    • MORE MERGERS, ACQUISITIONS AND LICENSING
    • POTENTIAL FIXED-DOSE COMBINATION DRUGS LEAD THE MARKET
    • LEADING MANUFACTURERS IN THE FIXED-DOSE COMBINATION DRUG MARKET
  • COMPANY PROFILES

LIST OF TABLES

• SUMMARY: FIXED-DOSE COMBINATION THERAPEUTICS, MARKET SHARE BY CATEGORY: 2006 AND 2012
• 1. SELECTED BRAND-NAME FIXED-DOSE COMBINATION PRODUCTS, BY THERAPEUTIC CATEGORY
• 2. THE MARKET FOR FIXED-DOSE COMBINATION THERAPEUTICS, BY CATEGORY: WORLDWIDE SALES: 2005-2012
• 3. EFFECTS OF ANTIHYPERTENSIVE AGENTS ON SELECTED CORONARY RISK FACTORS
• 4. CLASSIFICATION OF BLOOD PRESSURE FOR ADULTS AGED 18 YEARS AND OLDER
• 5. BRAND-NAME FIXED-DOSE COMBINATION ANTIHYPERTENSIVE DRUGS: WORLDWIDE MARKET, 2005, 2006, 2007 AND 2012
• 6. STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.
• 7. BRAND-NAME FIXED-DOSE COMBINATION DRUGS TO TREAT HYPERCHOLESTEROLEMIA, BY PRODUCT: WORLDWIDE SALES, 2005, 2006, 2007 AND 2012
• 8. BRAND-NAME FIXED-DOSE COMBINATION DRUGS TO TREAT DIABETES: WORLDWIDE SALES, 2005, 2006, 2007 AND 2012
• 9. SELECTED FIXED-DOSE COMBINATION DRUGS TO TREAT INFECTIOUS BACTERIAL DISEASES, BY PRODUCT: WORLDWIDE SALES, 2005, 2006, 2007 AND 2012
• 10. BRAND-NAME FIXED-DOSE COMBINATION DRUGS TO TREAT H. PYLORI INFECTIONS: WORLDWIDE SALES, 2005, 2006, 2007 & 2012
• 11. ESTIMATED NUMBER OF PERSONS INFECTED WITH HIV/LIVING WITH AIDS, ADULTS AND CHILDREN, BY GEOGRAPHIC REGION: 2005
• 12. PERCENT OF GLOBAL HIV CASES BY GEOGRAPHIC REGION: 2005
• 13. ESTIMATED NUMBER OF PEOPLE NEWLY INFECTED WITH HIV, ADULTS AND CHILDREN, BY GEOGRAPHIC REGION: 2005
• 14. ESTIMATED NUMBER OF DEATHS FROM AIDS, ADULTS AND CHILDREN, BY GEOGRAPHIC REGION: 2005
• 15. ESTIMATED NUMBER OF PEOPLE INFECTED WITH HIV IN SELECTED COUNTRIES: 2002 AND 2010
• 16. NUMBER OF DEATHS FROM AIDS IN THE U.S., 1987-2005
• 17. PRODUCT INTRODUCTIONS FOR THE TREATMENT OF HIV INFECTION, U.S.: 2002-2005
• 18. DAILY DOSAGE REQUIREMENTS FOR SELECTED HIV/AIDS THERAPIES
• 19. RELATIONSHIP BETWEEN COMPLIANCE AND DOSING FREQUENCY
• 20. FDA-APPROVED FIXED DOSE COMBINATION DRUGS FOR THE TREATMENT OF HIV INFECTION/AIDS
• 21. BRAND-NAME FIXED-DOSE HIV/AIDS THERAPEUTICS: WORLDWIDE SALES, BY PRODUCT: 2005-2012
• 22. HIV/AIDS THERAPEUTICS BY PRODUCT CATEGORY: WORLDWIDE SALES, 2005-2012
• 23. FIRST-LINE FIXED-DOSE COMBINATION DRUGS FOR THE TREATMENT OF TUBERCULOSIS
• 24. BRAND-NAME FIXED-DOSE PSYCHIATRIC THERAPEUTICS: WORLDWIDE SALES: 2005-2012
• 25. DRUG COMBINATIONS STUDIED IN THE TREATMENT OF ALZHEIMER' S DISEASE
• 26. ASTHMA DRUG CATEGORIES AND SELECTED PRODUCTS
• 27. SELECTED BRANDED ANTI-INFLAMMATORY AND BRONCHODILATING DRUGS USED TO TREAT ASTHMA
• 28. DRUGS USED TO TREAT ASTHMA, BY CATEGORY: WORLDWIDE SALES, 2005, 2006, 2007 AND 2012
• 29. DRUGS USED TO TREAT COPD, BY CATEGORY, 2005, 2006, 2007 AND 2012
• 30. BRAND-NAME FIXED-DOSE COMBINATION DRUGS TO TREAT ASTHMA/COPD, BY PRODUCT: WORLDWIDE SALES, 2005, 2006, 2007 AND 2012
• 31. FIXED-DOSE COMBINATION PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ASTHMA AND/OR COPD

LIST OF FIGURES

• SUMMARY FIGURES
• 1. MARKET SHARE FOR DRUGS TO TREAT ASTHMA, BY CATEGORY OF DRUG, WORLDWIDE, 2006 AND 2012
• 2. MARKET SHARE FOR DRUGS TO TREAT COPD, BY CATEGORY OF DRUG, WORLDWIDE, 2006 AND 2012